Evaluation of platelet function under high shear condition in the small-sized collagen bead column.

[1]  A. Federici.  Clinical diagnosis of von Willebrand disease , 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

[2]  D. Lillicrap,et al.  von Willebrand disease: laboratory aspects of diagnosis and treatment , 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

[3]  J. Moake.  von Willebrand factor, ADAMTS-13, and thrombotic thrombocytopenic purpura. , 2004, Seminars in hematology.

[4]  Y. Yatomi,et al.  Mechanisms of platelet retention in the collagen-coated–bead column , 2003 .

[5]  H. Kwaan,et al.  Hyperviscosity in polycythemia vera and other red cell abnormalities. , 2003, Seminars in thrombosis and hemostasis.

[6]  Z. Ruggeri,et al.  Von Willebrand factor, platelets and endothelial cell interactions , 2003, Journal of thrombosis and haemostasis : JTH.

[7]  S. Jackson,et al.  Signaling events underlying thrombus formation , 2003, Journal of thrombosis and haemostasis : JTH.

[8]  T. Barbui,et al.  Chronic myeloproliferative disorders. , 2003, Hematology. American Society of Hematology. Education Program.

[9]  J. Sadler.  A new name in thrombosis, ADAMTS13 , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[10]  B. Jilma.  Platelet function analyzer (PFA-100): a tool to quantify congenital or acquired platelet dysfunction. , 2001, The Journal of laboratory and clinical medicine.

[11]  C. Gachet.  ADP Receptors of Platelets and their Inhibition , 2001, Thrombosis and Haemostasis.

[12]  E. Favaloro,et al.  Appropriate laboratory assessment as a critical facet in the proper diagnosis and classification of von Willebrand disorder. , 2001, Best practice & research. Clinical haematology.

[13]  Z. Ruggeri.  Structure of von Willebrand factor and its function in platelet adhesion and thrombus formation. , 2001, Best practice & research. Clinical haematology.

[14]  Jan Kroon,et al.  Identification of the Collagen-binding Site of the von Willebrand Factor A3-domain* , 2001, The Journal of Biological Chemistry.

[15]  D. Gastineau,et al.  How important are ABO‐related variations in coagulation factor levels? , 2001, Transfusion.

[16]  Pille Harrison,et al.  Progress in the assessment of platelet function. , 2000, British journal of haematology.

[17]  A. Ahlbom,et al.  Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[18]  K. Titani,et al.  Activation of protein-tyrosine kinase pathways in human platelets stimulated with the A1 domain of von Willebrand factor. , 2000, Platelets.

[19]  T. Ohmori,et al.  Involvement of proline-rich tyrosine kinase 2 in platelet activation: tyrosine phosphorylation mostly dependent on alphaIIbbeta3 integrin and protein kinase C, translocation to the cytoskeleton and association with Shc through Grb2. , 2000, The Biochemical journal.

[20]  K. Titani,et al.  ABO blood group antigens on human plasma von Willebrand factor after ABO-mismatched bone marrow transplantation. , 1999, Blood.

[21]  A. Folsom,et al.  Prospective study of markers of hemostatic function with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. , 1999, Circulation.

[22]  H. Yamamoto,et al.  AJvW-2, an anti-vWF monoclonal antibody, inhibits enhanced platelet aggregation induced by high shear stress in platelet-rich plasma from patients with acute coronary syndromes. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[23]  S. Goto,et al.  Enhanced shear-induced platelet aggregation in acute myocardial infarction. , 1999, Circulation.

[24]  M. Frojmovic.  Platelet aggregation in flow: differential roles for adhesive receptors and ligands. , 1998, American heart journal.

[25]  B. Coller,et al.  Monitoring platelet GP IIb/IIIa antagonist therapy. , 1998, Circulation.

[26]  R. Knöfler,et al.  Release of adenosine triphosphate by adenosine diphosphate in whole blood and in erythrocyte suspensions , 1997, American journal of hematology.

[27]  S. Duffy,et al.  Von Willebrand factor and risk of ischemic stroke , 1997, Neurology.

[28]  A. Folsom,et al.  Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. , 1997, Circulation.

[29]  M. Carr.  In vitro assessment of platelet function. , 1997, Transfusion medicine reviews.

[30]  Brian Savage,et al.  Initiation of Platelet Adhesion by Arrest onto Fibrinogen or Translocation on von Willebrand Factor , 1996, Cell.

[31]  P. Southern,et al.  Whole-blood platelet aggregation predicts in vitro and in vivo primary hemostatic function in the elderly. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[32]  S. Uchiyama,et al.  Shear‐Induced Platelet Aggregation in Cerebral Ischemia , 1994, Stroke.

[33]  J. Jansson,et al.  von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. , 1991, British heart journal.

[34]  K Watanabe,et al.  The role of von Willebrand factor and fibrinogen in platelet aggregation under varying shear stress. , 1991, The Journal of clinical investigation.

[35]  M. Naka,et al.  Effects of ONO-3708, an antagonist of the thromboxane A2/prostaglandin endoperoxide receptor, on platelet aggregation and thrombosis. , 1989, European journal of pharmacology.

[36]  J. Moake,et al.  Shear-induced platelet aggregation can be mediated by vWF released from platelets, as well as by exogenous large or unusually large vWF multimers, requires adenosine diphosphate, and is resistant to aspirin , 1988 .

[37]  W. Marks,et al.  The effect of ABO blood group on the diagnosis of von Willebrand disease. , 1987, Blood.

[38]  D. Wagner,et al.  VON WILLEBRAND FACTOR RELEASED FROM WEIBEL-PALADE BODIES BINDS MORE AVIDLY TO EXTRACELLULAR MATRIX THAN THAT SECRETED CONSTITUTIVELY , 1987, Thrombosis and Haemostasis.

[39]  J. Moake,et al.  Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation. , 1986, The Journal of clinical investigation.

[40]  J. Sixma,et al.  Adhesion of platelets to human artery subendothelium: effect of factor VIII-von Willebrand factor of various multimeric composition. , 1984, Blood.

[41]  Z. Ruggeri,et al.  Variant von Willebrand's disease: characterization of two subtypes by analysis of multimeric composition of factor VIII/von Willebrand factor in plasma and platelets. , 1980, The Journal of clinical investigation.

[42]  K. Brinkhous,et al.  Nature of von Willebrand factor: a new assay and a specific inhibitor. , 1974, Proceedings of the National Academy of Sciences of the United States of America.

[43]  H. Weiss,et al.  Quantitative assay of a plasma factor deficient in von Willebrand's disease that is necessary for platelet aggregation. Relationship to factor VIII procoagulant activity and antigen content. , 1973, The Journal of clinical investigation.

[44]  E. Rossi,et al.  A Study of Platelet Retention by Glass Bead Columns (‘Platelet Adhesiveness’ in Normal Subjects) , 1972, British journal of haematology.

[45]  A. Hellem.  Platelet adhesiveness in von Willebrand's disease. A study with a new modification of the glass bead filter method. , 2009, Scandinavian journal of haematology.

[46]  J. V. van Mourik,et al.  Purification of human antihemophilic factor (factor VIII) by gel chromatography. , 1970, Biochimica et biophysica acta.

[47]  E. Salzman.  MEASUREMENT OF PLATELET ADHESIVENESS. A SIMPLE IN VITRO TECHNIQUE DEMONSTRATING AN ABNORMALITY IN VON WILLEBRAND'S DISEASE. , 1963, The Journal of laboratory and clinical medicine.

[48]  G. Born,et al.  Aggregation of Blood Platelets by Adenosine Diphosphate and its Reversal , 1962, Nature.